Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin versus placebo for symptom improvement in diarrhea-predominant irritable bowel syndrome
IRCT20250405065221N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifaximin in Diarrhea-predominant irritable bowel syndrome (IBS-D) (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: IBS-SSS score. Started Apr 2025; status: completed.
02
Drugs
rifaximin
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on IRCT20250405065221N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250405065221N1.